Does Oncternal Therapeutics' (NASDAQ:ONCT) Share Price Gain of 84% Match Its Business Performance?
-
Summary:
While Oncternal Therapeutics, Inc. (NASDAQ:ONCT) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 11% in the last quarter. While that might be a setback, it doesn't negate the nice returns received over the last twelve months. To wit, it had solidly beat the market, up 84%.
View our latest analysis for Oncternal Therapeutics
Oncternal Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that ...